Avalo Therapeutics Inc (AVTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Avalo Therapeutics Inc stock (AVTX) is currently trading at $13.45. Avalo Therapeutics Inc PS ratio (Price-to-Sales) is 1293.96. Analyst consensus price target for AVTX is $36.11. WallStSmart rates AVTX as Sell.
- AVTX PE ratio analysis and historical PE chart
- AVTX PS ratio (Price-to-Sales) history and trend
- AVTX intrinsic value — DCF, Graham Number, EPV models
- AVTX stock price prediction 2025 2026 2027 2028 2029 2030
- AVTX fair value vs current price
- AVTX insider transactions and insider buying
- Is AVTX undervalued or overvalued?
- Avalo Therapeutics Inc financial analysis — revenue, earnings, cash flow
- AVTX Piotroski F-Score and Altman Z-Score
- AVTX analyst price target and Smart Rating
Avalo Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Avalo Therapeutics Inc (AVTX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Avalo Therapeutics Inc (AVTX) Key Strengths (1)
122.91% of shares held by major funds and institutions
Supporting Valuation Data
Avalo Therapeutics Inc (AVTX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -66.40%, a shrinking business
Very expensive at 1294.0x annual revenue
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
Avalo Therapeutics Inc (AVTX) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (1293.96), Price/Book (2.73) suggest expensive pricing. Growth concerns include Revenue Growth at -66.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -174.80%, Operating Margin at -34632.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -174.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -66.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AVTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AVTX's Price-to-Sales ratio of 1293.96x trades 18% below its historical average of 1581.85x (0th percentile). The current valuation is 25% below its historical high of 1733.64x set in Mar 2026, and 0% above its historical low of 1293.96x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1700.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Avalo Therapeutics Inc (AVTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Avalo Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 192,000 with 66% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 6911% of revenue (13M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 66% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -14M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Avalo Therapeutics Inc.
Bottom Line
Avalo Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Avalo Therapeutics Inc(AVTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Avalo Therapeutics Inc is a pioneering clinical-stage biotechnology company focused on developing innovative therapies for rare and underserved conditions, particularly in the realm of immunological regulation. With a robust pipeline of proprietary candidates targeting serious diseases with significant unmet medical needs, Avalo leverages its deep expertise in disease mechanisms to advance its therapeutic programs through rigorous clinical trials. The company's dedication to scientific innovation and a patient-centric approach positions it to navigate the complexities of the biopharmaceutical industry effectively, with the goal of delivering transformative therapies to improve patient outcomes.